Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)

Peer Review reports

Original Submission
6 Jan 2022	Submitted	Original manuscript
3 Apr 2022	Author responded	Author comments - yang ZhengYang
Resubmission - Version 2
3 Apr 2022	Submitted	Manuscript version 2
7 Apr 2022	Author responded	Author comments - yang ZhengYang
Resubmission - Version 3
7 Apr 2022	Submitted	Manuscript version 3
Publishing
17 Apr 2022	Editorially accepted
27 Apr 2022	Article published	10.1186/s12885-022-09554-9

Back to article page